Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of OCR-002 in Cirrhosis
NCT03846843Phase 1Completed
- Sponsor
- Ocera Therapeutics
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ornithine phenylacetate in Cirrhosis (7 arms), sponsored by Ocera Therapeutics. Primary endpoints: Maximum Plasma Concentration at 5 days, Time to Maximum Concentration at 5 days and 5 more. Started Aug 2016; status: completed.
02
Drugs
ornithine phenylacetate
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT03846843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846843.